FATE - フェイト・セラピュ―ティクス (Fate Therapeutics Inc.) フェイト・セラピュ―ティクス

 FATEのチャート


 FATEの企業情報

symbol FATE
会社名 Fate Therapeutics Inc (フェイト・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 フェイト・セラピューティクス(Fate Therapeutics Inc)は臨床段階のバイオ医薬品会社である。同社はがんおよび免疫障害のためのプログラム細胞免疫療法の開発に従事する。同社の細胞治療パイプラインは改変誘導多能性細胞による癌免疫療法を含む免疫腫瘍学プログラム、造血細胞移植を受けている患者の免疫系を保護し、自己免疫を抑制するための造血細胞免疫療法を含む免疫調節プログラムを含む。リード臨床プログラムはプログラム免疫調節細胞療法であるProTmuneである。同社は細胞プログラミング手法を利用して、CD34 +細胞、ナチュラルキラー(NK)細胞およびT細胞などの免疫細胞をプログラムする。養子細胞治療プログラムは、治療機能を調節し、免疫細胞のフェイトを導くために適用される同社の体外細胞プログラミングアプローチに基づく。   フェイト・セラピュ―ティクスは、米国のバイオベンチャ―企業。幹細胞関連で先進的な医薬品の創製を目指す。造血幹細胞の移植後の定着を高める作用を持つ幹細胞調整薬「FT 1050」の開発などに注力。なお、人工多能性幹細胞(iPS細胞)の作製にかかわる実験法の特許を所有する。本社は、カリフォルニア州サンディエゴ。   Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company's immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company's immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease. Fate Therapeutics is headquartered in San Diego, CA.
本社所在地 3535 General Atomics Court Suite 200 San Diego CA 92121 USA
代表者氏名 William H. Rastetter ウィリアムH.ラスターセッター
代表者役職名 Independent Chairman of the Board
電話番号 +1 858-875-1803
設立年月日 39173
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数 80人
url www.fatetherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/fate
adr_tso
EBITDA EBITDA(百万ドル) -55.14200
終値(lastsale) 14.96
時価総額(marketcap) 799151067.44
時価総額 時価総額(百万ドル) 888.97060
売上高 売上高(百万ドル) 4.10600
企業価値(EV) 企業価値(EV)(百万ドル) 825.80060
当期純利益 当期純利益(百万ドル) -56.97000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Fate Therapeutics Inc revenues remained flat at $2.1M. Net loss increased 71% to $33.8M. Revenues reflect market conditions. Higher net loss reflects Research_Development increase of 81% to $26.6M (expense) Other general_Administrative Expenses increase of 24% to $6.2M (expense) Stock-based Compensation in SGA increase of 75% to $1.2M (expense).

 FATEのテクニカル分析


 FATEのニュース

   RGNX, FATE and ALVR are among after hours  2022/05/06 21:50:34 Seeking Alpha
Gainers: REGENXBIO (RGNX) +8%. Passage Bio (PASG) +6%
   Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q1 2022 Results - Earnings Call Transcript  2022/05/05 03:53:05 Seeking Alpha
Fate Therapeutics, Inc. (NASDAQ:NASDAQ:FATE) Q1 2022 Earnings Conference Call May 4, 2022 17:00 ET Company Participants Bob Valamehr - Chief Research & Development Officer Scott Wolchko…
   Fate Therapeutics GAAP EPS of -$0.68 beats by $0.11, revenue of $18.4M beats by $9.39M  2022/05/04 20:05:38 Seeking Alpha
Fate Therapeutics press release (NASDAQ:FATE): Q1 GAAP EPS of -$0.68 beats by $0.11.Revenue of $18.4M (+65.2% Y/Y) beats by $9.39M.
   Fate Therapeutics Reports First Quarter 2022 Financial Results and Highlights Operational Progress  2022/05/04 20:01:00 GlobeNewswire
FT596+R Enrollment Ongoing in Single- and Multi-dose, Multi-cycle Cohorts for R/R BCL
   Fate Therapeutics Q1 2022 Earnings Preview (NASDAQ:FATE)  2022/05/03 21:35:32 Seeking Alpha
Fate Therapeutics (FATE) is scheduled to announce Q1 earnings results on Wednesday, May 4th, after market close.The consensus EPS Estimate is -$0.74 and the consensus Revenue Estimate…
   Fate Therapeutics (NASDAQ:FATE) Posts Earnings Results, Beats Estimates By $0.13 EPS  2021/11/07 19:14:41 Dakota Financial News
Fate Therapeutics (NASDAQ:FATE) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.45) EPS for the quarter, topping analysts consensus estimates of ($0.58) by $0.13, MarketWatch Earnings reports. Fate Therapeutics had a negative return on equity of 29.21% and a negative net margin of 359.66%. The business had revenue of $14.23 million for []
   Brokerages Set Fate Therapeutics, Inc. (NASDAQ:FATE) Target Price at $110.17  2021/11/07 13:32:51 Dakota Financial News
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) have been given an average rating of Buy by the twenty brokerages that are presently covering the company, MarketBeat reports. Six investment analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that []
   Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q3 2021 Results - Earnings Call Transcript  2021/11/05 04:29:05 Seeking Alpha
   Fate Therapeutics EPS beats by $0.13, beats on revenue  2021/11/04 20:06:40 Seeking Alpha
   Fate Therapeutics Announces Eight Presentations at the 2021 ASH Annual Meeting  2021/11/04 13:01:00 Intrado Digital Media
FT596 Oral and FT516 Poster Presentations to Highlight Updated Clinical Data for Relapsed / Refractory Lymphoma on Monday, December 13
   Dowling & Yahnke Llc Buys Vanguard S&P 500 ETF, Fate Therapeutics Inc, MicroStrategy ...  2021/07/21 18:38:07 GuruFocus
Related Stocks: VOO , VEA , TMUS , ACWV , SQ , NOW , FATE , MSTR , AMD , LUMN , BX , SPTM , GWPH , NMFC , TSLX , BABA , TSM , CRWD ,
   Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell Lymphoma  2021/07/16 12:00:00 Intrado Digital Media
SAN DIEGO, July 16, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that management will host a virtual event to highlight interim Phase 1 clinical data from its FT596 and FT516 programs for the treatment of relapsed / refractory B-cell lymphomas on August 19, 2021 at 4:30 p.m. ET.
   Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2021 Financial Results  2021/07/15 20:01:00 Intrado Digital Media
SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that the Company will host a conference call and live audio webcast on Wednesday, August 4, 2021 at 5:00 p.m. ET to report its second quarter 2021 financial results and provide a corporate update.
   Induced Pluripotent Stem Cells (iPSCs) Market Overview, Size, Share Opportunities and Challenges By Major Players Fujifilm Holding Corporation (CDI), Ncardia, Sumitomo Dainippon Pharma, Astellas Pharma Inc, Fate Therapeutics, Inc, etc.  2021/07/12 05:03:20 Tramways Monthly
Industry Growth Insights (IGI) published a latest research report on Induced Pluripotent Stem Cells (iPSCs) Market 2021. The Research Report is a comprehensive and in-depth analysis of the global Induced Pluripotent Stem Cells (iPSCs) Market. The report provides detailed information about current trends, drivers, and challenges facing this industry. This research not only helps companies []
   Hedge Funds Have Never Been This Bullish On Fate Therapeutics Inc (FATE)  2021/06/28 13:31:59 Insider Monkey

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 フェイト・セラピュ―ティクス FATE Fate Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)